”After years of research we suddenly realised how to combine our findings. It was a eureka moment.”

Introducing Amferia wound dressing for animal care — binds and kills bacteria without harming the body

How antimicrobial hydrogel can revolutionize clinical treatments

Binds and kills 99.99% of bacteria without harming the body – even resistant bacteria

”After years of research we suddenly realised how to combine our findings. It was a eureka moment.”

The Amferia story:

Amferia was born in Gothenburg, Sweden, when three PhD researchers who had been collaborating for five years, had the idea to combine their findings. After several conversations among themselves, in 2016 Amferia founders Saba Atefyekta, Anand Kumar Rajasehkaran and Martin Andersson, conceived a new class of antimicrobial material while working at Chalmers University of Technology .

The approach was to utilise antimicrobial peptides—a potent antimicrobial molecule that Saba Atefyekta was investigating for biomaterial applications — in combination with a new amphiphilic hydrogel developed by Anand Rajasekharan for his PhD research on synthetic bone.

Within the first two weeks, we noted that the idea was sound and worked perfectly, which is a rarity in science” 

During a conference visit to Montreal in May 2016, Saba, Anand and Martin dove deeper into discussions and realized their combined research had uncovered potential for real-world biomedical applications. ”After all these years of research we suddenly realised how to combine our findings. It was a eureka moment.”

Excited by their discoveries, Saba and Anand returned to the lab and initiated the first trial runs, synthesizing the material and testing it on bacteria.“Within the first two weeks, we noted that the idea was sound and worked perfectly, which is a rarity in science.” 

From basic research to a high-impact product

The company:

After months of trials and more trials focused on optimizing the commercial viability of the product, the founders knew their idea had life beyond the lab and science publications. They knew they could develop a new, innovative product to target and kill bacteria in medical applications.  

The team immediately reached out to the innovation arm of Chalmers University and filed for a patent. Then they engaged in intense market research, while continuing further experiments on resistant bacteria.

By late 2017, the first patent was filed, the hydrogel had been proven to kill bacteria — including numerous resistant bacteria — and was safely used in biological environments without toxicity. Most importantly, the founders agreed their first product using the new technology should address wound care.

By late 2017, the first patent was filed, the material proven to kill bacteria including numerous resistant bacteria

Since then, the company has worked hard and successfully scaled the technology, completed clinical evaluations in both human and animal wound care and are now preparing for their regulatory approvals.  

With further support from Chalmers innovation Office and a seed funding from Chalmers Ventures, Amferia was officially incorporated in September 2018. Both Anand and Saba, completed their PhDs and jumped on board to continue their full-time journey, translating fundamental research into new products for human and animal health.

Today Amferia is a talented team of seven, with dedicated personnel for business development, sales, clinical development, product development and production. 

Protected by strong patents granted in Europe and the U.S.

Patent portofolio:

Amferia’s innovation is protected by three strong patent families. The basic patent is already in force in the U.S. and Europe, and pending in several other countries. Ongoing R&D continues to generate new patent applications.

Currently, strong patent protection extends over Amferia’s core technology and key intellectual property, creating the potential for rapid and robust growth into human and animal health care. Because the patents extend to both the U.S. and Europe, Amferia is poised to enter partnerships that enable market leadership well into the future.  

Amferia's patent families

  • — Antimicrobial hydrogel technology (Application nr. 17512773) was filed in 6 countries and granted in 2022 in Europe and the US, pending in the remaining countries with expected outcome in late 2022. The patent is the foundation of Amferia's innovation and claims a new amphiphilic antimicrobial material, a device comprising the antimicrobial material and a method to produce the same.
  • — Mesoporous elastomer technology is Amferia's second patent family that claims a tough and nanostructured elastomeric material for various medical device applications.
  • — Utilizing antimicrobial technology in spray form was filed in 2020 and is currently granted in Sweden (1951495-9) and expected to be granted in other countries by early 2023. Utilizing the Amferia antimicrobial technology in spray form that can be applied to deeper wounds, bleeding wounds and surfaces for rapid disinfection.

Named by the science journal Nature and others

Recognition:

Amferia has been recognised by numerous organisations for its innovative research, entrepreneurial drive, business traction in multiple sectors and swift progress towards clinical translation. 

During 2019, Venture Cup Sweden named Amferia as the ‘Startup-of-the year  while the scientific journal Nature named Amferia as ‘one-to-watch  — on a list of the top 44 pioneering university spin-offs with excellent scientific groundwork

Amferia’s Co-founder and Sales Director, Dr. Saba Atefyekta, was recognised as a pioneering female entrepreneur by Women-in Tech Sweden and the Prince Daniel Fellowship.

Meet the team

Team and board:

Anand Rajasekharan, PhD, CEO & Co-founder. Anand holds a PhD in Materials Science from Chalmers University of Technology and is one of the inventors of the material platform serving Amferia’s healthcare technology.

Saba Atefyekta, PhD, Sales Director & Co-founder. Co- inventor behind Amferia’s technology.  Holds a PhD in Materials Science from Chalmers University and her thesis describes the antimicrobial platform of Amferia’s technology. Today, she leads business development in human and animal health.

Martin Andersson, PhD, R&D Director & Co-founder. Fifteen years’ experience in biomedical research with 100 scientific publications. He has previously started a med-tech company for bone implants with successful implementation of products into the market. Professor, Materials Science at Chalmers University.

Daniel Hagberg, PhD, CTO. Ten years experience in product development and manufacturing from the speciality chemicals and healthcare industry. PhD in Materials Science from Royal Institute of Technology, Sweden

Rojan Modaresi, DVM, PhD, Product Manager, Animal Health.  Responsible for Amferia’s wound products for animal care and works at the interface between product development and customer interaction at veterinary clinics across Europe. Doctor of Veterinary Medicine and PhD in microbiology from Urmia University, Iran.

Annija Stepulane, MSc., Research Engineer. Responsible for material testing and biological evaluation of pipeline products.  MSc. in Materials Chemistry from Chalmers University.

Edvin Blomstrand, MSc., Lic., Research Engineer. Responsible for the product design and device optimization for wound care applications. Skilled in material design, antimicrobial testing and cell-material assessment. Licentiate of Engineering from Chalmers University.

Stefan Adolfsson, Sales, USA. Amferia's representative for sales and business development for the US market. Stefan comes from over 20 years working in leadership positions in manufacturing and sales from healthcare and material engineering industry.

Board of Directors

Agneta Edberg, Chair. Previously Nordic Senior VP of Mylan, COO Bactiguard, Marketing Director at Pharmacia, Pfizer and CEO NM Pharma and several life science board assignments

Björn Engström. Previously Co-founder and Copywriter at Forsman & Bodenfors, several board assignments in scale-up companies and experienced in life-science marketing

Saba Atefyekta, PhD, Co-founder. PhD in Materials Science from Chalmers University and co-inventor of Amferia Technology

Martin Andersson, PhD, Co-founder. Professor in Materials Science at Chalmers University and co-inventor of Amferia Technology. Co-founder of Promimic AB, an bone-implant scale-up.

Louise Warme, MD. Previously Investment Manager at Almi Invest and Medical Doctor. Co-founded LARA Diagnostics

Strong support for Amferia

Partners and funding:

Agneta Edberg appointed chairperson

July 28, 2022

Agneta has a solid background from the global Life science and Medtech field spanning over 30 years in leading roles such as; Sales &Marketing Director of Pharmacia (Pfizer), Senior VP and CEO of Mylan NordicPharmaceuticals, CEO of NM Pharma and more recently as the COO of Bactigaurd that manufactures a variety of antimicrobial device. Today, she works on theBoard of cutting-edge life-science SME’s guiding the companies for future success. Agneta’s extensive knowledge in the life science industry will be important for Amferia’s scale-up journey in both human and animal wound care.

Anand Kumar Rajasekharan, CEO of Amferia − “It is an honour to work with Agenta, whose impressive knowledge of the field and guidance greatly strengthens Amferia’s position as a competent and cutting-edge SME. We look forward to jointly achieve the upcoming key milestones such as the first product launch for animal health, FDA and CE regulatory processes for human health and establishing a successful sales and marketing foundation for Amferia.”

Agneta Edberg − “Amferia is a company every board person wishes to work for. The technology offers a paradigm shift in wound care with nontoxic properties still killing bacteria, even the resistant ones. In a world where antimicrobial resistance is an increasing challenge to humanity, I am grateful to be a part of reducing that threat”

Amferia at the European Wound Management Association (EWMA) congress 2022 in Paris

May 17, 2022

EWMA is an important congress that brings together clinicians and healthcare  industry for important discussions within wound care for humans and animals. Amferia is eager to present our science, antimicrobial technology and introduce our first wound dressings for animal and human wound  care. We welcome all attendees to our stand located in

room 252A at the  congress venue, Palais  des Congrès de Paris, to know more about Amferia and  clinical evidence for human and animal wound care as well as for an  introduction to our soon-to-be launched wound dressings for animal wound  care. We also invite all  attendees to our scientific talk at the symposium for Veterinary Wound  Healing Association (VWHA) on 24th May at 08:45 hrs room 252A.

Amferia granted US patent for its antimicrobial material platform

May 9, 2022

Amferia AB announced today that it has been granted the foundational patent by the United States Patent and Trademark Office (USPTO)for its innovative antimicrobial material based on an amphiphilic antimicrobial hydrogel. The company is now in its final stages of product development for wound care applications and aims to launch the first product within animal health during 2022.

Top 100 research based innovations of 2021

May 26, 2021

Amferia’s technology recognized as one of the top 100 research based innovations of 2021 by the Royal Swedish Academy of Engineering Sciences.

Amferia & Triolab announce partnership to launch innovative wound care products for animal health

May 6, 2021

The joint partnership with Triolab will enable Amferia to reach the large Swedish veterinary market where wound care and infection prevention is of prime importance, which has been intensified with the growing threat of antibiotic resistant infections. Amferia and Triolab’s partnership will build on extensive data and feedback from Amferia’s ongoing product trials across Europe. The joint efforts will aim to market the products to selective veterinary clinics across Sweden during 2021 and further expansion in 2022.

Amferia raises SEK 6.2 million in pre-seed investment

January 22, 2020

Almi Invest, Chalmers Ventures, along with the British investor Corithinan Properties Ltd. and Let’s Deal Founder Alexander Hars have invested a total of SEK 6.2 million in the Gothenburg-based med-tech company Amferia, who has developed a wound care product with a patented material that actively combats infections and kills antibiotic-resistant bacteria.

“Every year, 700,000 people die globally as a result of infections caused by antibiotic-resistant bacteria and almost half of the infections begin with a simple wound on the skin. Amferia's wound care solution is a game-changer and will save lives”, says Louise Warme, Investment Manager at Almi Invest.

Amferia establishes R&D operations at AstraZeneca’s BioVentureHub

October 28, 2019

Amferia is very excited to move into the BioVentureHub, given the strong benefits of operating in a flourishing environment with state-of-the-art infrastructure dedicated to medtech and life science companies. We are also eager to be around so many experts within life science ranging from established to early-stage companies researching in biopharmaceuticals, medical devices and diagnostics. Amferia looks forward to be part of, learn and grow in this supportive and exciting community.

At the Annual Veterinary Hygiene Conference 2019

October 24, 2019

We had the pleasure to attend the annual Veterinary Hygiene Conference in Knivsta, Stockholm. One of the primary questions of this conference was about handling antibiotic resistant infections in animal wound care – a fast growing problem in Sweden and Globally. Many interesting & enlightening discussions with expert veterinary clinicians taught us a lot about the needs and challenges in animal wound care and how Amferia might expand its innovative solutions to help veterinary healthcare. Thanks for a great conference VVHF.

Amferia wins the Start-up of the Year award at Venture Cup Sweden 2019

September 20, 2019

The Jury's motivation for choosing Amferia as the winners! “With its disruptive solution, the team has the opportunity to shake several industries as they tackle one of humanity’s greatest global threats. By addressing a world problem, millions of lives will be saved. By changing the behavior of the consumer, there is also the potential to reform the market.”

Amferia receives the prestigious EU SME Instrument (Phase 1) grant from the European Union

August 1, 2019

Amferia receives the highly competitive and coveted EU SME Instrument Phase 1 grant of 50 000 Euros along with the valuable business network to take forward our technology into the market.